Basilea is well on track to deliver on its new strategy to become a pure-play anti-invectives R&D company with sustainable profits from 2023 onwards. Currently, revenues are primarily driven by Cresemba. Zevtera’s revenues should get a considerable boost upon launch in the lucrative US market.
Key catalysts include:
1. Cresemba approval in Japan (Q4 2022)
2. Repayment 2022 convertible bond (December 2022)
3. US filing of Zevtera for severe bacterial infections (around year-end 2022)